Park and colleagues evaluated the effect of neoadjuvant chemotherapy for thymic cancers, comparing postoperative outcomes and long-term survival between 102 matched pairs of patients who underwent either upfront resection or resection after neoadjuvant chemotherapy. Postoperative complications and hospital length of stay were similar between the groups, as were three-year recurrence-free survival and five-year overall survival.
You are here:
Comparison of Neoadjuvant Chemotherapy Followed by Surgery to Upfront Surgery for Thymic Malignancy
Submitted by: Claire Vernon
Source: The Annals of Thoracic Surgery
Source URL: https://doi.org/10.1016/j.athoracsur.2018.08.055
Keywords:
Author(s): Samina Park, In Kyu Park, Young Tae Kim, Geun Dong Lee, Dong Kwan Kim, Jong Ho Cho, Yong Soo Choi, Chang Young Lee, Jin Gu Lee, Chang Hyun Kang, for the Korean Association for Research on the Thymus
